Free Trial

Orgenesis (ORGS) Competitors

$0.70
0.00 (0.00%)
(As of 07/19/2024 ET)

ORGS vs. CEMI, CLRB, ACRS, IFRX, ANIX, CKPT, BNTC, IOBT, BYSI, and CASI

Should you be buying Orgenesis stock or one of its competitors? The main competitors of Orgenesis include Chembio Diagnostics (CEMI), Cellectar Biosciences (CLRB), Aclaris Therapeutics (ACRS), InflaRx (IFRX), Anixa Biosciences (ANIX), Checkpoint Therapeutics (CKPT), Benitec Biopharma (BNTC), IO Biotech (IOBT), BeyondSpring (BYSI), and CASI Pharmaceuticals (CASI). These companies are all part of the "pharmaceutical preparations" industry.

Orgenesis vs.

Orgenesis (NASDAQ:ORGS) and Chembio Diagnostics (NASDAQ:CEMI) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, community ranking, valuation, profitability, risk, dividends, earnings and analyst recommendations.

22.6% of Orgenesis shares are owned by institutional investors. Comparatively, 8.6% of Chembio Diagnostics shares are owned by institutional investors. 5.7% of Orgenesis shares are owned by insiders. Comparatively, 3.3% of Chembio Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Orgenesis
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Chembio Diagnostics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Chembio Diagnostics received 272 more outperform votes than Orgenesis when rated by MarketBeat users. However, 100.00% of users gave Orgenesis an outperform vote while only 52.50% of users gave Chembio Diagnostics an outperform vote.

CompanyUnderperformOutperform
OrgenesisOutperform Votes
1
100.00%
Underperform Votes
No Votes
Chembio DiagnosticsOutperform Votes
273
52.50%
Underperform Votes
247
47.50%

Chembio Diagnostics has higher revenue and earnings than Orgenesis.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Orgenesis$529K45.58-$55.36MN/AN/A
Chembio Diagnostics$48.34M0.35-$23.29M-$1.20-0.38

In the previous week, Orgenesis' average media sentiment score of 0.00 equaled Chembio Diagnostics'average media sentiment score.

Company Overall Sentiment
Orgenesis Neutral
Chembio Diagnostics Neutral

Chembio Diagnostics has a net margin of -47.03% compared to Orgenesis' net margin of -1,343.97%. Orgenesis' return on equity of 0.00% beat Chembio Diagnostics' return on equity.

Company Net Margins Return on Equity Return on Assets
Orgenesis-1,343.97% N/A -503.42%
Chembio Diagnostics -47.03%-113.57%-38.22%

Orgenesis has a beta of 1.23, meaning that its stock price is 23% more volatile than the S&P 500. Comparatively, Chembio Diagnostics has a beta of 1.85, meaning that its stock price is 85% more volatile than the S&P 500.

Summary

Chembio Diagnostics beats Orgenesis on 6 of the 11 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ORGS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ORGS vs. The Competition

MetricOrgenesisPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$24.11M$7.05B$5.30B$8.38B
Dividend YieldN/A2.85%2.76%3.96%
P/E RatioN/A20.32124.9118.23
Price / Sales45.58310.262,172.5889.22
Price / CashN/A32.4036.5233.62
Price / Book-1.065.734.894.42
Net Income-$55.36M$147.21M$112.28M$216.15M
7 Day Performance-5.15%-2.42%-0.66%-0.11%
1 Month Performance14.75%5.52%7.27%5.51%
1 Year Performance-35.78%-4.09%6.33%1.70%

Orgenesis Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CEMI
Chembio Diagnostics
0 of 5 stars
0.00 / 5 stars
$0.46
flat
N/A+0.0%$16.71M$48.34M-0.38337Analyst Forecast
CLRB
Cellectar Biosciences
1.5885 of 5 stars
1.59 / 5 stars
$2.63
+0.4%
$20.00
+660.5%
+27.3%$94.29MN/A-0.8520News Coverage
ACRS
Aclaris Therapeutics
3.2041 of 5 stars
3.20 / 5 stars
$1.31
-0.8%
$22.25
+1,598.5%
-87.4%$94.07M$31.12M-1.20100
IFRX
InflaRx
2.6303 of 5 stars
2.63 / 5 stars
$1.59
flat
$13.50
+749.1%
-62.7%$93.62M$70,000.00-2.0462
ANIX
Anixa Biosciences
2.0237 of 5 stars
2.02 / 5 stars
$2.91
-7.6%
$7.00
+140.5%
-19.2%$93.15M$210,000.00-7.864News Coverage
CKPT
Checkpoint Therapeutics
3.4765 of 5 stars
3.48 / 5 stars
$2.58
-3.4%
$22.60
+777.7%
-21.8%$91.90M$100,000.00-0.9323Analyst Forecast
BNTC
Benitec Biopharma
1.4112 of 5 stars
1.41 / 5 stars
$9.65
-0.5%
$23.00
+138.3%
+167.2%$90.42M$80,000.000.0016News Coverage
IOBT
IO Biotech
3.2016 of 5 stars
3.20 / 5 stars
$1.37
+3.8%
$9.67
+605.6%
-16.0%$90.26MN/A-0.7368News Coverage
Positive News
BYSI
BeyondSpring
0 of 5 stars
0.00 / 5 stars
$2.31
+0.4%
N/A+103.7%$90.16M$1.75M0.0036Gap Down
CASI
CASI Pharmaceuticals
2.2833 of 5 stars
2.28 / 5 stars
$6.56
+4.3%
$6.00
-8.5%
+153.0%$87.90M$33.88M-2.88176Analyst Forecast
News Coverage

Related Companies and Tools

This page (NASDAQ:ORGS) was last updated on 7/21/2024 by MarketBeat.com Staff

From Our Partners